outlook kol call et
despit strong ytd perform share vs concern
competit landscap remain primari investor concern alexion investor day
week march help clarifi growth strategi highlight sever
pipelin opportun suspect wont directli address uncertainti
potenti competitor view alexion domin ultra-orphan space add
clinic develop commerci hurdl often overlook
slow pace progress competitor said list late-stage/advanc
program apelli achillion regeneron roch ra etc continu grow
address competit landscap impact host call well-
known kol dr anita hill focu recent launch ultomiri weve also
conduct npv sensit analysi base pt look rang
competit scenario includ signific eros soliris/ultomiri
franchis time new therapi add-on soliris/ultomiri
former npv impact high current share level
latter npv impact increment overal remain
confid competit front given robust ultomiri launch
accordingli weve rais pt weve also tweak
complement revenu mix modestli lower top line given lower ultomiri
price detail pleas join us et today discuss dr
anita hill leed teach hospit uk well also slide review
npv work dial us ou passcod
model updat model includ ultomiri gmg nmosd sale faster
pnh ahu switch given price discount lower forecast
project sale vs prior respect
adjust ep declin vs respect
quarterli annual ep usd
rais usd
return equiti ttm
link barclay live interact chart
consensu number refinitiv receiv gmt
barclay capit inc and/or one affili seek busi
compani cover research report result investor awar
firm may conflict interest could affect object report investor
consid report singl factor make invest decis
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
expans soliri pnh/ahu addit
growth driven sale gmg likley nmosd
assum robust convers ultomiri pnh
follow approv ahu evenut gmg/
nmosd support long-term viabil
complement franchis
greater expect growth soliri current
indic ahu pnh gmg approv nmosd
addit approv ultomiri
indic iv sc formul
faster expect entri biosimilars/novel
competitor entri market high price
pressur geographi addit develop
failur ultomiri gmg nmosd increas fx
headwind macroeconom issu support
downsid case
price target chang price target prior base sum-of-th part
npv analysi forecast sale soliri ultomiri strensiq
kanuma includ termin valu use discount rate vs
prior forecast period think appropri reflect risk portfolio
termin valu assum less growth rate discount rate
prior deriv valu prior soliri
prior ultomiri strensiq kanuma net
cash result total npv share
except per op analysisoldnewoldnewr barclay
geoff meacham ph herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens directli indirectli
relat specif recommend view express research report
barclay research produc invest bank barclay bank plc affili collect individu barclay
author contribut research report research analyst unless otherwis indic public date top report
reflect local time report produc may differ releas date provid gmt
avail disclosur
